CMS Should Fully Automate ASP Data Submissions, OIG Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Manufacturers’ submissions of average sales price data from drugs are entered manually by CMS staff; the HHS Inspector General recommends a fully automated process like the one used for average manufacturer price submissions.
You may also be interested in...
CMS Should Verify Part B Drug Pricing From Manufacturers, GAO Says
CMS 'concurs' with GAO’s recommendation on ASP reports but it’s unclear how much more aggressively it will pursue underlying documentation.
OIG Report Highlights Difficulty In Measuring “Widely Available Market Price” For Drugs
Limitations and irregularities in sales data prevent an accurate comparison of average sales price and widely available market price for Medicare Part B drugs, a differential that can be the basis for modifying reimbursement.
GSK's Nucala Is Significantly Overpriced, ICER Draft Report Finds
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.